This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles Marwick

JAMA. 1998;279:1937-1938.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE FIRST vaccine to be developed against Borrelia burgdorferi, the tick-borne spirochete that causes Lyme disease, should be licensed for marketing, an advisory committee told the Food and Drug Administration (FDA). But even as the committee voted unanimous agreement on the vaccine's safety and efficacy, members hedged their vote with a list of concerns about the usefulness of the vaccine and its long-term safety.

Lyme disease has been reported in 48 states, is endemic in the Northeast and California, and is spreading geographically from endemic areas to adjacent regions.

At the advisory committee meeting held May 26 in Bethesda, Md, Robert Schoen, MD, clinical professor of medicine at Yale University School of Medicine, New Haven, Conn, said there were 17500 cases reported to the Centers for Disease Control and Prevention (CDC) in 1996. Although the disease has been on the increase since the early 1980s and is now . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Occupational risk of Lyme disease: an epidemiological review
Piacentino and Schwartz
Occup. Environ. Med. 2002;59:75-84.
ABSTRACT | FULL TEXT  

Lyme Disease Vaccine: Good for Dogs, Adults, and Children?
Feder and MD
Pediatrics 2000;105:1333-1334.
FULL TEXT  

Lyme Disease Vaccine
Schofield et al.
JAMA 2000;283:199-200.
FULL TEXT